Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Background— Drug eluting stents with durable polymers may be associated with hypersensitivity, delayed healing, and incomplete endothelialization, which may contribute to late/very late stent thrombosis and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. The SYNERGY stent is a thin-strut, platinum chromium metal alloy platform with an ultrathin bioabsorbable Poly(D,L-lactide-co-glycolide) abluminal everolimus-eluting polymer. We performed a multicenter, randomized controlled trial for regulatory approval to determine noninferiority of the SYNERGY stent to the durable polymer PROMUS Element Plus everolimus-eluting stent. Methods and Results— Patients (n=1684) scheduled to undergo percutaneous coronary intervention for non–ST-segment–elevation acute coronary syndrome or stable coronary artery disease were randomized to receive either the SYNERGY stent or the PROMUS Element Plus stent. The primary end point of 12-month target lesion failure was observed in 6.7% of SYNERGY and 6.5% PROMUS Element Plus treated subjects by intention-to-treat ( P =0.83 for difference; P =0.0005 for noninferiority), and 6.4% in both the groups by per-protocol analysis ( P =0.0003 for noninferiority). Clinically indicated revascularization of the target lesion or definite/probable stent thrombosis were observed in 2.6% versus 1.7% ( P =0.21) and 0.4% versus 0.6% ( P =0.50) of SYNERGY versus PROMUS Element Plus–treated subjects, respectively. Conclusions— In this randomized trial, the SYNERGY bioabsorbable polymer everolimus-eluting stent was noninferior to the PROMUS Element Plus everolimus-eluting stent with respect to 1-year target lesion failure. These data support the relative safety and efficacy of SYNERGY in a broad range of patients undergoing percutaneous coronary intervention. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01665053.


  • Kereiakes, Dean J
  • Meredith, Ian T
  • Windecker, Stephan
  • Lee Jobe, R
  • Mehta, Shamir
  • Sarembock, Ian J
  • Feldman, Robert L
  • Stein, Bernardo
  • Dubois, Christophe
  • Grady, Timothy
  • Saito, Shigeru
  • Kimura, Takeshi
  • Christen, Thomas
  • Allocco, Dominic J
  • Dawkins, Keith D

publication date

  • April 2015

has subject area